<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5565427 - Stabilized factor VIII preparations - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Stabilized factor VIII preparations"><meta name="DC.contributor" content="Wilfried Freudenberg" scheme="inventor"><meta name="DC.contributor" content="Behringwerke Aktiengesellschaft" scheme="assignee"><meta name="DC.date" content="1994-4-29" scheme="dateSubmitted"><meta name="DC.description" content="The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof."><meta name="DC.date" content="1996-10-15" scheme="issued"><meta name="DC.relation" content="US:4650858" scheme="references"><meta name="DC.relation" content="US:4743680" scheme="references"><meta name="DC.relation" content="US:5110907" scheme="references"><meta name="citation_reference" content="H. Schwinn et al., Drug. Res., vol. 39 (II.), No. 10: 1302 1305 (1989)."><meta name="citation_reference" content="H. Schwinn et al., Drug. Res., vol. 39 (II.), No. 10: 1302-1305 (1989)."><meta name="citation_reference" content="Meyers, R. et al., &quot;Large Scale Preparation of a Highly Purified Solvent-Detergent Treated Factor VIII Concentrate,&quot; VOX Sang. vol. 60, pp. 141-147 (1991)."><meta name="citation_reference" content="Meyers, R. et al., Large Scale Preparation of a Highly Purified Solvent Detergent Treated Factor VIII Concentrate, VOX Sang. vol. 60, pp. 141 147 (1991)."><meta name="citation_patent_number" content="US:5565427"><meta name="citation_patent_application_number" content="US:08/235,241"><link rel="canonical" href="http://www.google.com/patents/US5565427"/><meta property="og:url" content="http://www.google.com/patents/US5565427"/><meta name="title" content="Patent US5565427 - Stabilized factor VIII preparations"/><meta name="description" content="The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof."/><meta property="og:title" content="Patent US5565427 - Stabilized factor VIII preparations"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("iyjuU-TqE-bAsQTFzoG4AQ"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("PRT"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("iyjuU-TqE-bAsQTFzoG4AQ"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("PRT"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5565427?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5565427"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=FbhABAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5565427&amp;usg=AFQjCNGXfH2jhgye8pRGgTb_mHFg0Y6uTw" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5565427.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5565427.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5565427" style="display:none"><span itemprop="description">The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof....</span><span itemprop="url">http://www.google.com/patents/US5565427?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5565427 - Stabilized factor VIII preparations</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5565427 - Stabilized factor VIII preparations" title="Patent US5565427 - Stabilized factor VIII preparations"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5565427 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/235,241</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Oct 15, 1996</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 29, 1994</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 9, 1991</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2065553A1">CA2065553A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2065553C">CA2065553C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE4111393A1">DE4111393A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE59209051D1">DE59209051D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0508194A1">EP0508194A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0508194B1">EP0508194B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08235241, </span><span class="patent-bibdata-value">235241, </span><span class="patent-bibdata-value">US 5565427 A, </span><span class="patent-bibdata-value">US 5565427A, </span><span class="patent-bibdata-value">US-A-5565427, </span><span class="patent-bibdata-value">US5565427 A, </span><span class="patent-bibdata-value">US5565427A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Wilfried+Freudenberg%22">Wilfried Freudenberg</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Behringwerke+Aktiengesellschaft%22">Behringwerke Aktiengesellschaft</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5565427.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5565427.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5565427.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (3),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (4),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (45),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (16),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (12)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5565427&usg=AFQjCNF4jMhz-ecCMhwd_2TKOVeZszWItQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5565427&usg=AFQjCNGKxZKn68cQI15h4RssAksoeiXWxQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5565427A%26KC%3DA%26FT%3DD&usg=AFQjCNHpWmpRZKibl9jzMxC5USiAY1jsUA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54106776" lang="EN" load-source="patent-office">Stabilized factor VIII preparations</invention-title></span><br><span class="patent-number">US 5565427 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37576122" lang="EN" load-source="patent-office"> <div class="abstract">The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(10)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5565427-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5565427-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(13)</span></span></div><div class="patent-text"><div mxw-id="PCLM5020835" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>I claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A stabilized solution with factor VIII:C activity containing factor VIII:C, an amino acid or one of its salts or homologs and a detergent or an organic polymer, wherein the specific factor VIII:C activity is at least 1000 IU/mg.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A solution as claimed in claim 1, wherein the amino acid is a natural amino acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A solution as claimed in claim 1, wherein the amino acid is a basic amino acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A solution as claimed in claim 1, which contains arginine and glycine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A solution as claimed in claim 1, wherein the concentration of the amino acid is 0.001 to 1 mol/l.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A solution as claimed in claim 1, which contains an organic polymer or a nonionic detergent.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A solution as claimed in claim 1, wherein the F VIII:C activity is derived (a) from human factor VIII in its form which occurs in plasma or (b) from a genetically engineered factor VIII:C or (C) from a homolog of (a) or (b).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. A pharmaceutical containing a solution as claimed in claim 1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A pharmaceutical as claimed in claim 8 further containing pharmaceutically compatible, stabilizing or buffering substances.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. A pharmaceutical as claimed in claim 9, which contains a carbohydrate.</div>
    </div>
    </div> <div class="claim"> <div num="11" class="claim">
      <div class="claim-text">11. A process for the preparation of a stable factor VIII:C solution which comprises adding an amino acid or one of its salts or homologs and an organic polymer or a detergent to a solution with factor VII I:C activity, wherein the specific factor VIII:C activity is at least 1000 IU/mg.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. A stabilized solution as claimed in claim 1 containing an amino acid or one of its salts or homologs and an organic polymer, wherein the amino acid is arginine or glycine and the organic polymer is polyethylene glycol.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. A stabilized solution as claimed in claim 1 containing an amino acid or one of its salts or homologs and a detergent, wherein the amino acid is arginine or glycine and the detergent is polyoxyethylene sorbitan mono-oleate.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66838340" lang="EN" load-source="patent-office" class="description">
    <p>This application is a continuation of application Ser. No. 08/082,911 filed Jun. 29, 1993, now abandoned, which is a continuation of application Ser. No. 07/864,610, filed Apr. 7, 1992, abandoned.</p>
    <p>The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof.</p>
    <p>Coagulation factor VIII:C (F VIII:C) is a plasma protein and essential for the process of the intrinsic pathway of blood coagulation. A deficiency or a defect in blood coagulation factor VIII:C results in a life-threatening disturbance of blood coagulation, hemophilia A. Concentrates of F VIII:C from human plasma or genetically engineered F VIII:C are employed for the therapy of hemophilia A.</p>
    <p>These F VIII products differ in respect of their purity, i.e. the presence of proteins which do not have coagulation activity in addition to the active substance F VIII:C. A F VIII which has more than 1000 U/mg before stabilization with albumin is called very high purity F VIII (VHP F VIII:C) (WHO, Expert Committee on Biological Standardization).</p>
    <p>Such VHP F VIII:C have potential advantages in the treatment of hemophilia. These are the freedom from viruses and a very small content of foreign protein, which means less stress on the immune system of the patients after administration of these concentrates. The advantage which is possible per se, of less stress on the immune system of a hemophiliac patient by administration of a F VIII preparation with high specific activity, is, however, cancelled out by addition of high albumin concentrations to the highly purified product in order to stabilize the VHP F VIII. This addition of albumin means that the highly purified F VIII concentrates reach specific activities of only 3-10 U/mg in the final formulation thereof.</p>
    <p>Although addition of albumin entails only a slight risk with respect to virus safety, it has to be borne in mind, however, that with albumin whose purity averages 95% once again unwanted concomitant proteins are administered to the patient and may stress his immune system.</p>
    <p>High purity F VIII product: which dispense with addition of albumin for stabilization of F VIII are known (Schwinn, Smith &amp; Wolter, Drug. Res. 39 (1989), 1302). These products reach specific activities of about 100 U/mg of protein. Based on a maximum achievable F VIII activity of about 5000 U/mg, this means that only about 2% of the protein content of these preparations comprises F VIII:C protein. It is to be assumed in this case that this 2% F VIII:C is stabilized by the 98% concomitant proteins, because a large part of these concomitant proteins is likely to comprise yon Willebrand Factor (vWF). It is known that von Willebrand Factor has a stabilizing action on F VIII:C.</p>
    <p>The situation is different with very high purity products which have specific activities which, before albumin stabilization, are usually more than 25 times higher than for high purity products, and the vWF content thereof is very low. This low vWF content is no longer able to ensure adequate F VIII stabilization so that the F VIII activity in solutions which are not stabilized with albumin rapidly decreases.</p>
    <p>The object of the present invention was therefore to provide a process which makes it possible to prepare a highly concentrated, physiologically tolerated solution of a VHP F VIII:C product, which solution requires no addition of proteins for stabilization.</p>
    <p>This object is achieved according to the invention by adding an amino acid or one of its salts, derivatives or homologs to a VHP F VIII:C preparation. It is possible to add L- and/or D-amino acids. Particular suitable are arginine, lysine, ornithine, guanidinoacetic acid or others whose common feature is a basic group in the form of an amino and/or guanidino group.</p>
    <p>The invention therefore relates to a solution with factor VIII:C activity containing an amino acid or one of its salts or derivatives and, ;here appropriate, a detergent or an organic polymer.</p>
    <p>Preferred embodiments are:</p>
    <p>a solution wherein the amino acid is a natural amino acid;</p>
    <p>a solution wherein the amino acid is a basic amino acid;</p>
    <p>a solution which contains arginine and glycine;</p>
    <p>a solution wherein the concentration of the amino acid is 0.001 to 1 mol/l;</p>
    <p>a solution which additionally contains an organic polymer or a nonionic detergent;</p>
    <p>a solution wherein the F VIII:C activity derives from human factor VIII in its form which occurs in plasma or from a genetically engineered factor VIII:C or a derivative of these;</p>
    <p>and a solution wherein the specific F VIII:C activity is at least 1000 IU/mg.</p>
    <p>Improved stabilization is achieved by combination of amino acids or their derivatives or with a nonionic detergent such as <sup>R</sup> Polysorbate 20 or <sup>R</sup> Polysorbate 80 or an organic polymer such as polyethylene glycol 1500.</p>
    <p>A combination of the amino acids arginine and glycine, preferably 0.01 to 1 mol/l, with the nonionic detergent <sup>R</sup> Tween 80, preferably 0.001 to 0.5% (v/v), and with a neutral sugar such as sucrose, preferably 0.1 to 10%, has proven particularly suitable for the preparation of a stable, albumin-free VHP F VIII:C solution.</p>
    <p>The pH of a solution of this type is adjusted to between pH 5.5 and 8.5, preferably between pH 6.5 and 7.5, by means of an organic acid, preferably 10% strength acetic acid.</p>
    <p>The invention also relates to a pharmaceutical containing a solution of this type. Besides a solution of this type, this pharmaceutical can contain customary, pharmaceutically compatible, stabilizing and/or buffering substances, especially a carbohydrate.</p>
    <p>The invention likewise relates to a process for the preparation of a solution of this type, wherein an amino acid or one of its salts or derivatives and, where appropriate, an organic polymer or a detergent is added to a solution with factor VIII:C activity.</p>
    <p>The advantageous effect of the process according to the invention can be shown, for example, for a F VIII:C preparation which has been purified by chromatography on monoclonal anti-F VIII:C antibodies, it being possible for the F VIII:C to be both obtained from plasma and genetically engineered, for example in CHO (Chinese Hamster Ovary) cells. This entails, for example, equal parts of a solution of the abovementioned substances being added to the eluate from the monoclonal antibody column, and subsequently the latter being dialyzed against this solution. The stabilized F VIII:C preparation obtained in this way can be sterilized by filtration and bottled with low method-related losses. A lyophilizate of this preparation obtained in this way has unchanged high F VIII:C activities after dissolution.</p>
    <p>It is possible with the process according to the invention to prepare a VHP F VIII:C preparation whose specific volume-based activity is at least 200 IU/ml, with a specific activity of more than 2000 IU/mg. This concentration ensures that there are no problems with manipulation owing to the need to administer small volumes.</p>
    <p>A preparation of this type does not need further stabilization by proteins, which avoids the risk of virus contamination. At the same time, the reduction in the high protein load means a considerable reduction in the stress on the immune system of the patient due to the addition of the albumin, which is unnecessary for the medicinal action, and of the unwanted impurities contained therein.</p>
    <p>Since physiologically tolerated substances are added for the stabilization, no intolerance reactions occur on administration of the solution according to the invention.</p>
    <heading>EXAMPLE 1</heading> <p>Two VHP F VIII:C preparations were prepared, both by means of affinity chromatography on monoclonal anti-vWF Ig (method of Fulcher &amp; Zimmermann PNAS (1982), 79, 1649) and dissociation of the vWF/F VIII:C complex by solution with a CaCl<sub>2</sub> concentration of 300 mM in 0.1 M acetate, 0.1 M lysine, pH 6.8 (eluate I), and by means of chromatography on monoclonal anti-F VIII:C Ig and elution of the F VIII:C by 50% ethylene glycol in 0.1 M acetate, 0.1 M lysine, pH 6.8 (eluate II). The specific F VIII:C activity determined in eluate I was 2500 IU/mg and 419 IU/ml, and in eluate II was 3280 IU/mg and 454 IU/ml. The two eluates were divided in each case. To one portion in each case was added in the ratio 1:1 by volume a 1% strength human albumin solution in 0.75% sucrose, 3% glycine and 0.1 mol/l NaCl (eluate I<sub>HSA</sub>, eluate II<sub>HSA</sub>). The stabilization buffer (0.75% sucrose, 3% glycine, 3% arginine, 0.05% <sup>R</sup> Tween 80, pH 6.8) was likewise added 1:1 to the other half in each case (eluate I<sub>S</sub>, eluate II<sub>S</sub>). The albumin-containing samples were dialyzed against 0.75% sucrose, 3% glycine, 0.1 mol/l NaCl, pH 6.8, and the others against stabilization buffer. Dialysis was carried out at 4Â° C. for 16 hours with 1000-fold volume change. The F VIII:C activities were measured before and after the dialysis. Table 1 shows the F VIII:C activity in % relative to the total F VIII:C activity in the particular sample before dialysis.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Eluate I<sub>HSA</sub>     Eluate I<sub>S</sub>                Eluate II<sub>HSA</sub>                           Eluate II<sub>S</sub>______________________________________92        94         94         93______________________________________</pre>
    
    <p>The results show that stabilization of the VHP F VIII:C eluates by means of the stabilization solution according to the invention is achieved irrespective of the preparation method and to the same extent as by addition of albumin.</p>
    <heading>EXAMPLE 2</heading> <p>An F VIII:C eluate with a specific F VIII:C activity of 3860 IU/mg of protein and 462 IU/ml was obtained after immunoaffinity chromatography on monoclonal anti-F VIII:C antibodies. Various stabilization solutions were added to this in the ratio 1:1 by volume, and it was dialyzed against the relevant stabilization solution as described in Example 1. A pH of 6.8 was adjusted in all solutions where appropriate with 10% acetic acid.</p>
    <p>The following stabilization solutions were employed:</p>
    <p>I. 0.75% sucrose, 0.4 M glycine, 0.15 M sodium chloride</p>
    <p>II. 0.01M sodium citrate, 0.08 M glycine, 0.016 M lysine, 0.0025 M calcium chloride, 0.4 M sodium chloride</p>
    <p>III. 1% sucrose, 0.14 M arginine, 0.1M sodium chloride</p>
    <p>IV. 1% sucrose, 0.4 M glycine, 0.14 M arginine, 0.1M sodium chloride, 0.05% Tween 80</p>
    <p>The F VIII:C activity was determined before and after the dialysis. In Table 2 the F VIII:C activity after dialysis is plotted in % relative to the relevant activity before dialysis.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________Mixture      I       II        III   IV______________________________________F VIII:C activity        39.3%   35.1%     82.4% 96.2%after dialysis for16 hours______________________________________</pre>
    
    <p>The solutions employed under I and II can be employed for the stabilization of albumin-free HP F VIII products with specific F VIII:C activities of 100-200 IU/mg, dispensing with addition of albumin. Solutions III and IV are suitable for stabilization of VHP F VIII preparations with specific F VIII:C activities greater than 1000 IU/mg.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4650858">US4650858</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 20, 1984</td><td class="patent-data-table-td patent-date-value">Mar 17, 1987</td><td class="patent-data-table-td ">Nordisk Gentofte A/S</td><td class="patent-data-table-td ">Precipitation with polyoxyethylene glycol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4743680">US4743680</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 1, 1985</td><td class="patent-data-table-td patent-date-value">May 10, 1988</td><td class="patent-data-table-td ">New York University</td><td class="patent-data-table-td ">Method for purifying antihemophilic factor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5110907">US5110907</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 1, 1989</td><td class="patent-data-table-td patent-date-value">May 5, 1992</td><td class="patent-data-table-td ">Alpha Therapeutic Corporation</td><td class="patent-data-table-td ">Factor viii complex purification using heparin affinity chromatography</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">H. Schwinn et al., Drug. Res., vol. 39 (II.), No. 10: 1302 1305 (1989).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">H. Schwinn et al., Drug. Res., vol. 39 (II.), No. 10: 1302-1305 (1989).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Meyers, R. et al., "<a href='http://scholar.google.com/scholar?q="Large+Scale+Preparation+of+a+Highly+Purified+Solvent-Detergent+Treated+Factor+VIII+Concentrate%2C"'>Large Scale Preparation of a Highly Purified Solvent-Detergent Treated Factor VIII Concentrate,</a>" VOX Sang. vol. 60, pp. 141-147 (1991).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Meyers, R. et al., Large Scale Preparation of a Highly Purified Solvent Detergent Treated Factor VIII Concentrate, VOX Sang. vol. 60, pp. 141 147 (1991).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5763401">US5763401</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 12, 1996</td><td class="patent-data-table-td patent-date-value">Jun 9, 1998</td><td class="patent-data-table-td ">Bayer Corporation</td><td class="patent-data-table-td ">Stabilized albumin-free recombinant factor VIII preparation having a low sugar content</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5770700">US5770700</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 25, 1996</td><td class="patent-data-table-td patent-date-value">Jun 23, 1998</td><td class="patent-data-table-td ">Genetics Institute, Inc.</td><td class="patent-data-table-td ">Liquid factor IX formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5874408">US5874408</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 28, 1998</td><td class="patent-data-table-td patent-date-value">Feb 23, 1999</td><td class="patent-data-table-td ">Bayer Corporation</td><td class="patent-data-table-td ">Stabilized albumin-free recombinant factor VII preparation having a low sugar content</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6372716">US6372716</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 1994</td><td class="patent-data-table-td patent-date-value">Apr 16, 2002</td><td class="patent-data-table-td ">Genetics Institute, Inc.</td><td class="patent-data-table-td ">Freeze dried mixture with glycine, polysorbate, sucrose, and histidine; storage stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6586573">US6586573</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2000</td><td class="patent-data-table-td patent-date-value">Jul 1, 2003</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Comprising a bulking agent, stabilizing agents, sodium chloride and a buffering agent; decreased risk of transmitting a virus; used in treating hemophilia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7087723">US7087723</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 2003</td><td class="patent-data-table-td patent-date-value">Aug 8, 2006</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Stable in the absence of albumin or other proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7199223">US7199223</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 2004</td><td class="patent-data-table-td patent-date-value">Apr 3, 2007</td><td class="patent-data-table-td ">Nektar Therapeutics Al, Corporation</td><td class="patent-data-table-td ">Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7220836">US7220836</a></td><td class="patent-data-table-td patent-date-value">Oct 6, 2003</td><td class="patent-data-table-td patent-date-value">May 22, 2007</td><td class="patent-data-table-td ">Quadrant Drug Delivery Limited</td><td class="patent-data-table-td ">Dried blood factor composition comprising trehalose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7244824">US7244824</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2003</td><td class="patent-data-table-td patent-date-value">Jul 17, 2007</td><td class="patent-data-table-td ">Quadrant Drug Delivery Limited</td><td class="patent-data-table-td ">Blood-coagulation factor VIII (or antihemophilic factor) containing trehalose stabilizer in absence of albumin; reconstitution with water</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7244825">US7244825</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 2003</td><td class="patent-data-table-td patent-date-value">Jul 17, 2007</td><td class="patent-data-table-td ">Quadrant Drug Delivery Limited</td><td class="patent-data-table-td ">Vial containing a dried native Factor VIII composition containing trehalose as a stabilizer and no albumin; may be reconstituted with water or brine for administration to a hemophilic patient by injection; stable at up to 60 degrees C.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7247707">US7247707</a></td><td class="patent-data-table-td patent-date-value">May 15, 2006</td><td class="patent-data-table-td patent-date-value">Jul 24, 2007</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Albumin-free factor VIII formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7253262">US7253262</a></td><td class="patent-data-table-td patent-date-value">Jun 25, 2001</td><td class="patent-data-table-td patent-date-value">Aug 7, 2007</td><td class="patent-data-table-td ">Quandrant Drug Delivery Limited</td><td class="patent-data-table-td ">Dried blood factor composition comprising trehalose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7381796">US7381796</a></td><td class="patent-data-table-td patent-date-value">Mar 23, 2007</td><td class="patent-data-table-td patent-date-value">Jun 3, 2008</td><td class="patent-data-table-td ">Quadrant Drug Delivery Limited</td><td class="patent-data-table-td ">Dried blood factor composition comprising trehalose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7501493">US7501493</a></td><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td patent-date-value">Mar 10, 2009</td><td class="patent-data-table-td ">Quadrant Drug Delivery Limited</td><td class="patent-data-table-td ">Dried blood factor composition comprising trehalose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7803911">US7803911</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2009</td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td ">Quandrant Drug Delivery Limited</td><td class="patent-data-table-td ">preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7858749">US7858749</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2007</td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7863421">US7863421</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2008</td><td class="patent-data-table-td patent-date-value">Jan 4, 2011</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Polymer-factor VIII moiety conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884075">US7884075</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2005</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Polymer-factor VIII-von Willebrand factor-conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8053561">US8053561</a></td><td class="patent-data-table-td patent-date-value">Mar 8, 2010</td><td class="patent-data-table-td patent-date-value">Nov 8, 2011</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Pegylated factor VIII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058226">US8058226</a></td><td class="patent-data-table-td patent-date-value">Jun 18, 2007</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">a mixture of antihemophilic factor, bulking agent selected from mannitol, glycine and alanine, stabilizer agents selected from sucrose, trehalose, raffinose and arginine, calcium chloride, sodium chloride and buffers, having storage stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8076463">US8076463</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 2011</td><td class="patent-data-table-td patent-date-value">Dec 13, 2011</td><td class="patent-data-table-td ">Baxter International, Inc.</td><td class="patent-data-table-td ">Polymer-von Willebrand factor-conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101718">US8101718</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 2009</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Emory University</td><td class="patent-data-table-td ">Methods of administering porcine B-domainless fVIII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8133977">US8133977</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 2009</td><td class="patent-data-table-td patent-date-value">Mar 13, 2012</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Polymer-factor VIII moiety conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8143378">US8143378</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 2009</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Polymer factor VIII moiety conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8187799">US8187799</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td patent-date-value">May 29, 2012</td><td class="patent-data-table-td ">Bayer Healthcare Llc</td><td class="patent-data-table-td ">Stabilization of liquid solutions of recombinant protein for frozen storage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8247536">US8247536</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 2009</td><td class="patent-data-table-td patent-date-value">Aug 21, 2012</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Factor VIII compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8357779">US8357779</a></td><td class="patent-data-table-td patent-date-value">Nov 28, 2011</td><td class="patent-data-table-td patent-date-value">Jan 22, 2013</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Polymer-von Willebrand factor-conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372800">US8372800</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 2011</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Albumin-free factor VIII formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8501694">US8501694</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2012</td><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">Emory University</td><td class="patent-data-table-td ">Method of administering porcine B-domainless fVIII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8519102">US8519102</a></td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td patent-date-value">Aug 27, 2013</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Polymer Factor VIII moiety conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8536125">US8536125</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 2012</td><td class="patent-data-table-td patent-date-value">Sep 17, 2013</td><td class="patent-data-table-td ">Bayer Healthcare Llc</td><td class="patent-data-table-td ">Stabilization of liquid solutions of recombinant protein for frozen storage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8618259">US8618259</a></td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td patent-date-value">Dec 31, 2013</td><td class="patent-data-table-td ">Nektar Therapeutics</td><td class="patent-data-table-td ">Polymer-factor VIII conjugate compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8697410">US8697410</a></td><td class="patent-data-table-td patent-date-value">Feb 10, 2012</td><td class="patent-data-table-td patent-date-value">Apr 15, 2014</td><td class="patent-data-table-td ">Bio-Rad Laboratories, Inc.</td><td class="patent-data-table-td ">SSO7-polymerase conjugates with decreased non-specific activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8765665">US8765665</a></td><td class="patent-data-table-td patent-date-value">Feb 6, 2013</td><td class="patent-data-table-td patent-date-value">Jul 1, 2014</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Albumin-free factor VIII formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110178019">US20110178019</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 3, 2009</td><td class="patent-data-table-td patent-date-value">Jul 21, 2011</td><td class="patent-data-table-td ">Brita Rippner</td><td class="patent-data-table-td ">New protecting compositions for recombinantly produced factor viii</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0710114A1?cl=en">EP0710114A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by third party"> â </span></td><td class="patent-data-table-td patent-date-value">Mar 31, 1994</td><td class="patent-data-table-td patent-date-value">May 8, 1996</td><td class="patent-data-table-td ">Pharmacia AB</td><td class="patent-data-table-td ">A coagulation factor viii formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1648485A2?cl=en">EP1648485A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by third party"> â </span></td><td class="patent-data-table-td patent-date-value">Jul 22, 2004</td><td class="patent-data-table-td patent-date-value">Apr 26, 2006</td><td class="patent-data-table-td ">Biotecon Therapeutics GmbH</td><td class="patent-data-table-td ">Formulation for a protein pharmaceutical without added human serum albumin (hsa)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2130554A1?cl=en">EP2130554A1</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2000</td><td class="patent-data-table-td patent-date-value">Dec 9, 2009</td><td class="patent-data-table-td ">University of Connecticut</td><td class="patent-data-table-td ">Novel albumin-free factor VIII formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2193809A1?cl=en">EP2193809A1</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2000</td><td class="patent-data-table-td patent-date-value">Jun 9, 2010</td><td class="patent-data-table-td ">University of Connecticut</td><td class="patent-data-table-td ">Albumin-free factor VIII formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2292216A2?cl=en">EP2292216A2</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2003</td><td class="patent-data-table-td patent-date-value">Mar 9, 2011</td><td class="patent-data-table-td ">Ipsen Pharma</td><td class="patent-data-table-td ">Stable pharmaceutical composition containing factor VIII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2616091A1?cl=en">EP2616091A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 16, 2011</td><td class="patent-data-table-td patent-date-value">Jul 24, 2013</td><td class="patent-data-table-td ">Baxter International Inc</td><td class="patent-data-table-td ">Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006071801A2?cl=en">WO2006071801A2</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2005</td><td class="patent-data-table-td patent-date-value">Jul 6, 2006</td><td class="patent-data-table-td ">Baxter Int</td><td class="patent-data-table-td ">Polymer-von willebrand factor-conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010144629A1?cl=en">WO2010144629A1</a></td><td class="patent-data-table-td patent-date-value">Jun 9, 2010</td><td class="patent-data-table-td patent-date-value">Dec 16, 2010</td><td class="patent-data-table-td ">Prolong Pharmaceuticals, LLC</td><td class="patent-data-table-td ">Hemoglobin compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011027152A1?cl=en">WO2011027152A1</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td ">Arecor Limited</td><td class="patent-data-table-td ">Stable formulation of factor viii</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013057219A1?cl=en">WO2013057219A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2012</td><td class="patent-data-table-td patent-date-value">Apr 25, 2013</td><td class="patent-data-table-td ">Csl Behring Gmbh</td><td class="patent-data-table-td ">Method for improving the stability of purified factor viii after reconstitution</td></tr></table><div class="patent-section-footer">* Cited by examiner, â  Cited by third party</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S013700">514/13.7</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S383000">530/383</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S021200">514/21.2</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009080000">A61K9/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038430000">A61K38/43</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0001020000">C07K1/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047180000">A61K47/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014755000">C07K14/755</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0007040000">A61P7/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038360000">A61K38/36</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047000000">A61K47/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047260000">A61K47/26</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038370000">A61K38/37</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=FbhABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/37">A61K38/37</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K38/37</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Apr 4, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 10, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIM 11 IS CONFIRMED. CLAIM 1 IS CANCELLED. CLAIMS 2-8, 10, 12 AND 13 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIM 9, DEPENDENT ON AN AMENDED CLAIM, IS DETERMINED TO BE PATENTABLE. NEW CLAIMS 14-23 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMA S.A., FRANCE</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:A. NATTERMANN UND CIE GMBH;REEL/FRAME:015232/0776</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040326</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMA S.A. 20, AVENUE RAYMOND ARONANOTNY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:A. NATTERMANN UND CIE GMBH /AR;REEL/FRAME:015232/0776</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 10, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 9, 2003</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20031021</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 21, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">A. NATTERMANN UND CIE GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS BEHRING GMBH;REEL/FRAME:013868/0331</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030319</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">A. NATTERMANN UND CIE GMBH NATTERMANNALLEE 1, D-50</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 23, 2002</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-13 IS CONFIRMED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 26, 2001</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010530</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 16, 2000</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS BEHRING GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CENTEON PHARMA GMBH;REEL/FRAME:010814/0231</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20000126</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS BEHRING GMBH P.O. BOX 1230 D 35002 MARBURG</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 15, 2000</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 5, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CENTEON PHARMA GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOECHST AKTIENGESELLSCHAFT;REEL/FRAME:008842/0126</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19971107</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 18, 1997</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U09WDCbSY7OALhI07Eoyx_LJOg8Cg\u0026id=FbhABAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0dgahPtEYCs39d8V-Wdbj9G7pMIA\u0026id=FbhABAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2znyzCKSE6-GyxYqPH6tN4V5PKOQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Stabilized_factor_VIII_preparations.pdf?id=FbhABAABERAJ\u0026output=pdf\u0026sig=ACfU3U2j6dYimzZpxE8hO4TRVpQhkRkJ-w"},"sample_url":"http://www.google.com/patents/reader?id=FbhABAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>